21 May 2022>: Clinical Research
Curative Analysis of Patients with Hepatocellular Carcinoma Using Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation
Yifan Li AE , Diwen Zhu BCD , Weixin Ren AE* , Junpeng Gu BCD , Weizheng Ji BCD , Haixiao Zhang BCD , Yingjun Bao BCD , Gengfei Cao BCD , Asihaer Hasimu BCDDOI: 10.12659/MSM.936246
Med Sci Monit 2022; 28:e936246
Table 1 Comparison of low-risk and high-risk groups receiving combined TACE and RFA therapy.
Variables | Total (n=142) | Low-risk (n=86) | High-risk (n=56) | Statistics | P |
---|---|---|---|---|---|
Sex, n (%) | χ=9.020 | 0.003 | |||
Female | 31 (21.83) | 26 (30.23) | 5 (8.93) | ||
Male | 111 (78.17) | 60 (69.77) | 51 (91.07) | ||
Age, Mean±SD | 59.90±10.57 | 61.38±10.19 | 57.63±10.83 | t=2.09 | 0.038 |
Tumor location, n (%) | χ=0.985 | 0.611 | |||
Right liver | 93 (65.49) | 59 (68.60) | 34 (60.71) | ||
Left liver | 17 (11.97) | 9 (10.47) | 8 (14.29) | ||
Bilateral liver | 32 (22.54) | 18 (20.93) | 14 (25.00) | ||
Tumor number, n (%) | χ=6.271 | 0.043 | |||
One | 98 (69.01) | 61 (70.93) | 37 (66.07) | ||
Two | 21 (14.79) | 8 (9.30) | 13 (23.21) | ||
Three or more | 23 (16.20) | 17 (19.77) | 6 (10.71) | ||
Tumor size, n (%) | χ=1.487 | 0.685 | |||
≤3 cm | 9 (6.34) | 7 (8.14) | 2 (3.57) | ||
3–5 cm | 54 (38.03) | 33 (38.37) | 21 (37.50) | ||
5–10 cm | 76 (53.52) | 44 (51.16) | 32 (57.14) | ||
>10 cm | 3 (2.11) | 2 (2.33) | 1 (1.79) | ||
PVTT, n (%) | χ=0.024 | 0.876 | |||
No | 125 (88.03) | 76 (88.37) | 49 (87.50) | ||
Yes | 17 (11.97) | 10 (11.63) | 7 (12.50) | ||
Hepatitis, n (%) | χ=3.571 | 0.059 | |||
No | 29 (20.42) | 22 (25.58) | 7 (12.50) | ||
Yes | 113 (79.58) | 64 (74.42) | 49 (87.50) | ||
Number of TACEs in the first treatment cycle, M (Q, Q) | 1.00 (1.00,1.00) | 1.00 (1.00,1.00) | 1.00 (1.00,1.00) | Z=−0.012 | 0.990 |
Number of RFAs in the first treatment cycle, M (Q, Q) | 1.00 (1.00,1.00) | 1.00 (1.00,2.00) | 1.00 (1.00,1.00) | Z=−4.738 | |
AFP, ng/ml, M (Q, Q) | 14.35 (4.40, 235.00) | 12.60 (3.60, 170.30) | 17.85 (4.90, 277.40) | Z=1.017 | 0.309 |
Tbil, μmol/L, M (Q, Q) | 16.50 (10.90, 20.80) | 16.05 (10.90, 22.06) | 16.85 (11.70, 20.27) | Z=0.054 | 0.957 |
Albumin, g/L, Mean±SD | 38.55±6.07 | 38.55±5.87 | 38.55±6.42 | t=0.00 | 0.998 |
ALT, U/L, M (Q, Q) | 25.36 (18.20, 39.69) | 22.69 (15.40, 35.04) | 37.25 (19.65, 51.22) | Z=3.465 | |
AST, U/L, M (Q, Q) | 30.60 (22.85, 42.50) | 27.70 (22.50, 40.50) | 33.20 (23.60, 44.10) | Z=2.039 | 0.041 |
LDH, U/L, Mean±SD | 189.82±41.75 | 189.73±41.59 | 189.96±42.37 | t=−0.03 | 0.975 |
ALP, U/L, M (Q, Q) | 91.50 (70.00, 126.00) | 87.50 (70.00, 116.70) | 100.95 (70.50, 139.95) | Z=1.062 | 0.288 |
Child-Pugh, n (%) | χ=0.367 | 0.545 | |||
A | 127 (89.44) | 78 (90.70) | 49 (87.50) | ||
B | 15 (10.56) | 8 (9.30) | 7 (12.50) | ||
BCLC, n (%) | χ=0.183 | 0.913 | |||
A | 69 (48.59) | 43 (50.00) | 26 (46.43) | ||
B | 58 (40.85) | 34 (39.53) | 24 (42.86) | ||
C | 15 (10.56) | 9 (10.47) | 6 (10.71) | ||
CNLC, n (%) | χ=2.967 | 0.563 | |||
Ia | 54 (38.03) | 35 (40.70) | 19 (33.93) | ||
Ib | 30 (21.13) | 18 (20.93) | 12 (21.43) | ||
IIa | 22 (15.49) | 10 (11.63) | 12 (21.43) | ||
IIb | 16 (11.27) | 11 (12.79) | 5 (8.93) | ||
IIIa | 20 (14.08) | 12 (13.95) | 8 (14.29) | ||
The outcome, n (%) | χ=48.964 | ||||
No progression or survival | 86 (60.56) | 72 (83.72) | 14 (25.00) | ||
Progression or death | 56 (39.44) | 14 (16.28) | 42 (75.00) | ||
PVTT – portal vein tumor thrombus; TACE – transarterial chemoembolization; RFA – radiofrequency ablation; AFP – alpha-fetoprotein; Tbil – total bilirubin; ALT – alanine transaminase; AST – aspartate transaminase; LDH – lactic dehydrogenase; ALP – alkaline phosphatase; BCLC – Barcelona Clinic Liver Cancer; CNLC – China liver cancer staging. |